Prostate Cancer Coverage from Every Angle

Does Enzalutamide Affect Metastasis-Free Survival in Men With Aggressive Prostate Cancer?

By: Kayci Reyer
Posted: Thursday, October 4, 2018

According to a study published in The New England Journal of Medicine, enzalutamide treatment in men with nonmetastatic, castration-resistant prostate cancer resulted in a 71% decrease in the risk of metastasis or death. Researchers sought to determine the drug’s effect on metastasis-free survival. Maha Hussein, MD, of Northwestern University, and colleagues also reported a “significant delay in the time to the first use of a subsequent antineoplastic therapy and in the time to [prostate-specific antigen] progression, with no difference in quality of life between the enzalutamide group and the placebo group.”

A total of 1,401 patients with nonmetastatic, castration-resistant prostate cancer participated in the study. Participants had a prostate-specific antigen (PSA) level doubling time no greater than 10 months. Participants were randomized 2:1 to receive enzalutamide (n = 933) or placebo (n = 468). All patients continued to receive androgen-deprivation therapy for the duration of the study.

In the enzalutamide group, the median metastasis-free survival was 36.6 months, versus 14.7 months in the placebo group (hazard ratio = 0.29). The enzalutamide group did not require the use of a subsequent antineoplastic therapy for 39.6 months, whereas the placebo group used such therapy at 17.7 months (hazard ratio = 0.21). The time to PSA progression was also longer for the enzalutamide group at 37.2 months versus 3.9 months for the placebo group (hazard ratio = 0.07). At the first assessment of overall survival, 11% of the patients treated with enzalutamide and 13% of patients receiving the placebo had died.

As for toxicity, 31% of patients taking enzalutamide reported adverse events grade 3 or higher, whereas 23% of the patients taking placebo reported the same. Fatigue was the only adverse event of any grade occurring in more than 20% of patients treated with enzalutamide.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.